Achillion Pharmaceuticals, Inc. (ACHN - Free Report) reported a loss of 16 cents per share in the second quarter of 2017, in line with the Zacks Consensus Estimate. In the year-ago quarter, the company had reported a loss of 14 cents per share.
The company generated no revenues in the reported quarter as had been the case in the year-ago quarter.
Shares of Achillion surged almost 28% in after-hours trading on Aug 8, as the company announced positive interim results on its most advanced factor D inhibitor pipeline candidate, ACH-4471. However, the stock has underperformed the industry year to date. The company’s shares lost 2.9% whereas the industry registered an increase of 8.7%.
Research and development expenses increased nearly 29% from the year-ago period to $18.3 million due to increased clinical trial costs related to pipeline candidate, ACH-4471. The increase in expenses also included higher manufacturing costs related to ACH-5528 and cost related to ophthalmic factor D inhibitor compounds in development. However, the increase was partially offset by a decrease in cost related to manufacturing of ACH-4471.
General and administrative expenses were up 4% to $5.4 million due to an increase in corporate legal fees and consulting fees, partially offset by a decrease in corporate taxes.
In April, Achillion initiated patient dosing in a phase II study, evaluating its key pipeline candidate, a factor D inhibitor, ACH-4471 for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). The company completed three months of dosing during the quarter and entered a long-term extension trial.
The interim results from the study, announced together with the earnings release, showed clinically meaningful complement inhibition and a favorable tolerability profile for ACH-4471. The candidate has shown improvement in LDH, hemoglobin, fatigue score and other markers of response.
Moreover, the company plans to initiate a phase II study later this year on ACH-4471 in patients with C3G, a rare renal disorder, which includes dense deposit disease (DDD) and C3 glomerulonephritis (C3GN).
Meanwhile, Achillion is planning to advance a number of next-generation factor D inhibitors in preclinical or clinical studies by 2017 end.
Also, Achillion is evaluating a triple combination of simeprevir, odalasvir and AL-335 in a phase II OMEGA-1 study in patients with HCV genotype 1, 2, 4, 5, and 6 infection, with and without cirrhosis. The study is being conducted by Johnson & Johnson’s (JNJ - Free Report) subsidiary Janssen with data expected in the second half of 2017.
Zacks Rank & Stocks to Consider
Achillion Pharma carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the pharma sector include Summit Therapeutics PLC (SMMT - Free Report) and Enzo Biochem, Inc. (ENZ - Free Report) . Both stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Summit’s loss estimates narrowed from $2.59 to 32 cents for 2017 over the last 60 days. The company delivered positive earnings surprise in each of the four trailing quarters with an average beat of 25.55%. Its share price is up 66.6% so far this year.
Enzo Biochem’s loss estimates narrowed from 12 cents to 7 cents for 2017 over the last 60 days. The company came up with a positive earnings surprise in all the four trailing quarters with an average beat of 55.83%. The stock is up 62.7% so far this year.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>